Method for Inducing T-Cell Proliferation


This technology relates to the use of thymic stromal lymphopoietin (TSLP) to induce CD4+ T cell proliferation. This proliferation could be of particular relevance for patients in whom this cell population has been significantly reduced by HIV/AIDS or other conditions resulting in immunodeficiency. The proliferation of isolated CD4+ T cells can be induced through direct contact with TSLP or a nucleic acid encoding TSLP. The patent application also describes methods of inducing or enhancing an immune response through administration of CD4+ T cells that have been isolated and induced to proliferate using TSLP or a nucleic acid encoding TSLP. TSLPR knockout mice are also described in the patent application and available for licensing through a biological materials license agreement.

Potential Commercial Applications: Competitive Advantages:
  • Immunotherapy
 


Development Stage:
In vivo data available (animal)

Inventors:

Warren Leonard (NHLBI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,731,953 issued 2010-06-08
US Application No. 11/084,408

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-104-2004-1
Updated: Sep 15, 2015